<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311269</url>
  </required_header>
  <id_info>
    <org_study_id>CL-001</org_study_id>
    <nct_id>NCT03311269</nct_id>
  </id_info>
  <brief_title>A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency</brief_title>
  <acronym>VICARES</acronym>
  <official_title>A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Insights, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Insights, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      VICARES is a prospective randomized, controlled, multi-center, double blind study treating
      venous insufficiency associated with incompetent saphenous veins with 1% and 3% Sodium
      Tetradecyl Sulfate (STS) solution utilizing the ClariVein system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 subjects diagnosed with an incompetent saphenous vein will be randomized to
      either 1% STS or 3% STS solution delivered by the ClariVein system under ultrasound guidance.

      Study duration for individual study patients, including follow-up visits, is anticipated to
      be approximately 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-Reported Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in patient reported symptoms using subset of the VEINES QOL/Sym Questionnaire at post treatment Week 12 compared to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination of saphenous vein reflux</measure>
    <time_frame>12 weeks</time_frame>
    <description>As demonstrated by duplex ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>ClariVein RES 1% Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Tetradecyl Sulfate 1% Injection single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ClariVein RES 3% Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Tetradecyl Sulfate 3% Injection single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClariVein RES</intervention_name>
    <description>ClariVein system</description>
    <arm_group_label>ClariVein RES 1% Injection</arm_group_label>
    <arm_group_label>ClariVein RES 3% Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Tetradecyl Sulfate 1% Injection</intervention_name>
    <description>Sodium Tetradecyl Sulfate STS 1% Injection</description>
    <arm_group_label>ClariVein RES 1% Injection</arm_group_label>
    <other_name>STS 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Tetradecyl Sulfate 3% Injection</intervention_name>
    <description>Sodium Tetradecyl Sulfate 3% Injection</description>
    <arm_group_label>ClariVein RES 3% Injection</arm_group_label>
    <other_name>STS 3%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patient with incompetent saphenous vein

          2. Saphenous vein reflux &gt; 500ms (0.5s), as measured by duplex ultrasound

          3. One or more of patient reported symptoms related to the target vein: i.e., heaviness,
             achiness, swelling, throbbing or itching.

          4. Candidate for endovenous procedure

        Exclusion Criteria:

          1. Arterial insufficiency demonstrated by a history of peripheral arterial disease (PAD)
             that would preclude the wearing of compression stockings

          2. Absence of a palpable pulse at posterior tibial or dorsalis pedis and an
             Ankle-Brachial Index (ABI) &lt;0.6

          3. Multi-segmental axial deep venous reflux in at least two contiguous venous segments
             (e.g., femoral and popliteal) in the ipsilateral extremity

          4. Previous surgical or endovenous procedure in the treatment section of the target vein

          5. Previous superficial thrombophlebitis of the target saphenous vein with scarring in
             the treatment section

          6. Pregnant or breastfeeding

          7. Known sensitivity or allergic response to Sodium Tetradecyl Sulfate (STS)

          8. Known high risk of thrombosis

          9. Known history of deep vein thrombus (DVT) or pulmonary embolism (PE), known history of
             acute superficial vein thrombus, known hypercoagulable condition, post thrombotic
             syndrome

         10. Known history of anaphylaxis or presence of multiple severe allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H Meissner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vascular and Endovascular Surgery Clinic at UWMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorraine M Hanley, MBA</last_name>
    <phone>203-446-4953</phone>
    <email>lhanley@vasularinsights.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nannette R Hayes, BS</last_name>
    <phone>203-446-4953</phone>
    <email>nannette@mccormicklifescience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Vascular Experts</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Myslinksi</last_name>
      <phone>203-956-6800</phone>
      <email>mmyslinski@thevascularexperts.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Obermayer</last_name>
      <email>lobermayer@thevascularexperts.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul J Gagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capitol Vein and Laser Centers</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Wilkinson, RN</last_name>
      <phone>301-695-8346</phone>
    </contact>
    <investigator>
      <last_name>Paul McNeill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Garth Rosenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Surgical Associates</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Potter</last_name>
      <phone>508-775-1984</phone>
      <email>donnamariepotter724@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Gorin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donna Potter</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Goodwin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Learned</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Peters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Englegwood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Lockwood</last_name>
      <phone>201-894-3852</phone>
      <email>&quot;Renee.Lockwood@ehmc.com&quot; &lt;Renee.Lockwood@ehmc.com&gt;;</email>
    </contact>
    <investigator>
      <last_name>Steven Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular, PLLC</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krissa Gunderson</last_name>
      <phone>425-453-1772</phone>
      <email>krissag@lkwv.com</email>
    </contact>
    <investigator>
      <last_name>Kathleen Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Ferris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renee Minjarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krissa Gunderson, CRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Stipek, CRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Tetradecyl Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

